Eagle Pharmaceuticals (EGRX) Short Interest Ratio & Short Volume $1.50 0.00 (0.00%) As of 10/14/2025 Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Eagle Pharmaceuticals Short Interest DataEagle Pharmaceuticals (EGRX) has a short interest of 42,200 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 13.6, indicating that it would take 13.6 days of the average trading volume of 6,606 shares to cover all short positions.Current Short Interest42,200 sharesPrevious Short Interest42,200 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$157.20 thousandShort Interest Ratio13.6 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares12,987,000 sharesPercentage of Shares Shorted0.32%Today's Trading Volume0 sharesAverage Trading Volume6,606 sharesToday's Volume Vs. Average0% Short Selling Eagle Pharmaceuticals? Sign up to receive the latest short interest report for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEGRX Short Interest Over TimeEGRX Days to Cover Over TimeEGRX Percentage of Float Shorted Over Time Eagle Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/202542,200 shares $157.20 thousand No ChangeN/A13.6 $3.73 8/31/202542,200 shares $130.40 thousand +0.2%0.5%105.5 $3.09 8/15/202542,100 shares $134.72 thousand -0.2%N/A38.3 $3.20 7/31/202542,200 shares $155.72 thousand -1.4%0.5%60.3 $3.69 7/15/202542,800 shares $160.07 thousand +1.4%N/A6.5 $3.74 6/30/202542,200 shares $122.38 thousand -0.7%0.5%9 $2.90 6/15/202542,500 shares $102 thousand No Change0.5%2.6 $2.40 5/31/202542,500 shares $80.75 thousand -21.9%0.5%6.4 $1.90 5/15/202554,400 shares $105.54 thousand -14.7%N/A24.7 $1.94 4/30/202563,800 shares $125.05 thousand -43.4%N/A2.3 $1.96 Get the Latest News and Ratings for EGRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 4/15/2025112,800 shares $203.04 thousand -0.1%N/A3.7 $1.80 3/14/2025112,500 shares $146.25 thousand No ChangeN/A13.4 $1.30 2/28/2025112,500 shares $135 thousand -8.8%N/A5.4 $1.20 2/14/2025123,400 shares $144.38 thousand -63.5%N/A8.2 $1.17 1/31/2025337,700 shares $270.16 thousand -6.5%N/A13.8 $0.80 1/15/2025361,000 shares $223.82 thousand +0.3%N/A34.7 $0.62 9/30/2024371,600 shares $1.39 million +6.0%2.9%1.7 $3.73 9/15/2024350,500 shares $1.51 million -17.3%3.1%2.4 $4.31 8/31/2024423,800 shares $2.18 million -12.5%3.7%2.9 $5.14 8/15/2024484,200 shares $1.93 million +14.1%4.2%3.1 $3.98 7/31/2024424,400 shares $2.05 million -44.9%3.7%2.5 $4.82 7/15/2024770,600 shares $4.60 million -16.8%6.7%4.5 $5.97 6/30/2024925,900 shares $5.19 million -6.9%8.1%5.2 $5.60 6/15/2024994,400 shares $3.83 million -7.9%8.7%6.7 $3.85 5/31/20241,080,000 shares $3.75 million -5.3%9.5%7.1 $3.47 5/15/20241,140,000 shares $5.26 million -5.0%10.0%7.8 $4.61 4/30/20241,200,000 shares $4.91 million +1.7%10.5%7.7 $4.09 4/15/20241,180,000 shares $6.14 million -2.5%10.3%5.9 $5.20 3/31/20241,210,000 shares $6.34 million +4.3%10.6%5.3 $5.24 3/15/20241,160,000 shares $7.02 million +4.5%10.2%5 $6.05 2/29/20241,110,000 shares $6.50 million +4.7%9.7%4.3 $5.86 2/15/20241,060,000 shares $6.20 million +33.2%9.3%3.6 $5.85 1/31/2024796,100 shares $4.67 million +10.1%7.0%2.8 $5.86 1/15/2024723,100 shares $3.28 million +3.7%6.4%2.9 $4.53 12/31/2023697,400 shares $3.65 million +3.9%6.2%3.4 $5.23 12/15/2023671,300 shares $3.11 million +13.7%5.9%3.6 $4.63 11/30/2023590,400 shares $3.45 million -0.7%5.2%3.9 $5.85 11/15/2023594,600 shares $5.25 million -3.7%5.2%5.2 $8.83 10/31/2023617,600 shares $8.48 million +2.4%5.5%5.8 $13.73 10/15/2023602,900 shares $8.10 million +12.5%5.3%4.9 $13.43 9/30/2023536,000 shares $8.45 million -23.9%4.7%4.1 $15.77 9/15/2023704,600 shares $11.42 million +9.9%6.2%5.2 $16.21 8/31/2023640,900 shares $10.86 million -6.1%5.7%3.3 $16.95 8/15/2023682,400 shares $11.63 million +4.5%6.0%3.4 $17.04 7/31/2023653,200 shares $13.56 million -4.0%5.7%3.2 $20.76 7/15/2023680,200 shares $12.50 million +14.6%6.0%3.6 $18.37 6/30/2023593,600 shares $11.54 million -26.9%5.2%3.2 $19.44 6/15/2023812,500 shares $15.41 million +18.6%7.1%4.2 $18.96 5/31/2023685,200 shares $14.22 million -1.3%6.0%4.1 $20.75 5/15/2023694,400 shares $14.60 million -3.0%6.1%4.3 $21.03 4/30/2023715,700 shares $20.10 million -5.1%6.3%4.7 $28.08 4/15/2023754,400 shares $22.41 million -19.7%6.7%4.8 $29.71 3/31/2023939,300 shares $26.65 million -7.9%8.3%5.5 $28.37 3/15/20231,020,000 shares $26.27 million +16.4%9.0%6.3 $25.75 2/28/2023876,100 shares $24.53 million +1.0%7.8%6.1 $28.00 2/15/2023867,400 shares $26.73 million -0.8%7.7%6.3 $30.82 1/31/2023874,400 shares $29.68 million -9.7%7.7%5.8 $33.94 1/15/2023968,700 shares $31.43 million -2.4%8.6%6.2 $32.45 12/30/2022992,100 shares $29.00 million +63.8%8.8%6.4 $29.23 12/15/2022605,700 shares $17.90 million -27.0%5.4%3.6 $29.55 11/30/2022830,100 shares $30.15 million -9.4%7.3%4.9 $36.32 11/15/2022915,900 shares $33.89 million +0.1%8.1%5.3 $37.00 10/31/2022915,200 shares $28.80 million -6.5%8.1%4.9 $31.47 10/15/2022978,700 shares $27.01 million +8.4%8.5%5.6 $27.60 9/30/2022903,200 shares $23.86 million +28.8%7.8%5.4 $26.42 9/15/2022701,400 shares $21.13 million -17.2%6.1%4.3 $30.12 8/31/2022846,900 shares $27.75 million +3.2%7.4%5.7 $32.77 8/15/2022820,900 shares $29.49 million -18.7%7.2%5.6 $35.92 7/31/20221,010,000 shares $40.10 million +1.0%9.2%7.4 $39.70 7/15/20221,000,000 shares $44.83 million -2.9%9.1%7.5 $44.83 6/30/20221,030,000 shares $45.76 million -7.2%9.4%7.6 $44.43 6/15/20221,110,000 shares $48.33 million +17.4%10.2%8 $43.54 5/31/2022945,600 shares $44.16 million +4.3%8.6%6.8 $46.70 5/15/2022906,800 shares $39.90 million +8.2%8.3%6.8 $44.00 4/30/2022838,200 shares $36.99 million +20.1%7.7%6.4 $44.13 4/15/2022697,800 shares $35.20 million -3.1%6.4%5.5 $50.44 3/31/2022719,800 shares $35.62 million +4.4%N/A5.5 $49.49 3/15/2022689,700 shares $34.69 million +14.0%6.3%5.9 $50.30 2/28/2022604,900 shares $28.67 million -10.2%5.4%4.8 $47.39 2/15/2022673,200 shares $32.15 million +1.1%6.0%5.6 $47.76 1/31/2022665,700 shares $30.58 million +12.4%5.9%5.9 $45.94 1/15/2022592,400 shares $27.97 million +2.3%N/A5.6 $47.21 12/31/2021579,300 shares $29.50 million -1.0%5.2%6 $50.92 12/15/2021585,100 shares $30.60 million -5.5%5.2%5.8 $52.30 11/30/2021618,900 shares $29.51 million -3.3%5.5%7.1 $47.68 11/15/2021639,900 shares $32.62 million -7.1%5.7%6.9 $50.98 10/29/2021689,000 shares $36.08 million -1.7%6.0%7 $52.37 10/15/2021701,000 shares $38.12 million -11.3%6.1%7 $54.38 9/30/2021790,700 shares $44.11 million -4.8%6.9%7.6 $55.78 9/15/2021830,500 shares $43.92 million -3.3%7.3%7.2 $52.88 8/31/2021859,200 shares $45.86 million -6.7%7.5%7.4 $53.37 8/13/2021920,800 shares $44.91 million -5.0%8.1%7.7 $48.77 7/30/2021969,000 shares $45.06 million +4.6%8.5%8.5 $46.50 7/15/2021926,100 shares $43.55 million -3.1%8.1%8.1 $47.02 6/30/2021955,800 shares $40.91 million -7.2%8.4%8.1 $42.80 6/15/20211,030,000 shares $42.73 million -2.8%9.0%9.3 $41.49 5/28/20211,060,000 shares $42.00 million -1.9%9.3%10.1 $39.62 5/14/20211,080,000 shares $43.92 million +2.9%9.4%9.8 $40.67 4/30/20211,050,000 shares $42.98 million -7.9%9.2%9.1 $40.93 4/15/20211,140,000 shares $49.44 million -16.8%N/A0 $43.37 3/31/20211,370,000 shares $56.25 million -2.1%12.2%11.2 $41.06 3/15/20211,400,000 shares $62.97 million No Change12.4%11 $44.98 2/26/20211,400,000 shares $64.09 million +7.7%12.4%10.8 $45.78 2/12/20211,300,000 shares $62.41 million -7.1%11.6%10.7 $48.01 1/29/20211,400,000 shares $65.63 million -2.1%12.4%11.7 $46.88 1/15/20211,430,000 shares $72.54 million -4.0%12.7%11.4 $50.73 12/31/20201,490,000 shares $69.29 million No Change13.2%11.5 $46.50 12/15/20201,490,000 shares $68.81 million -0.7%13.2%10.6 $46.18 11/30/20201,500,000 shares $70.97 million -3.9%13.3%10.2 $47.31 11/15/20201,560,000 shares $76.30 million -4.9%13.8%9.6 $48.91 10/30/20201,640,000 shares $75.74 million -12.3%14.5%9.8 $46.18 10/15/20201,870,000 shares $85.03 million -18.0%15.9%10.6 $45.47 EGRX Short Interest - Frequently Asked Questions What is Eagle Pharmaceuticals' current short interest? Short interest is the volume of Eagle Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of September 15th, traders have sold 42,200 shares of EGRX short. Learn More on Eagle Pharmaceuticals' current short interest. What is a good short interest ratio for Eagle Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EGRX shares currently have a short interest ratio of 14.0. Learn More on Eagle Pharmaceuticals's short interest ratio. How does Eagle Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Eagle Pharmaceuticals: Citius Oncology, Inc. (1.23%), Incannex Healthcare Inc. (7.55%), Nuvectis Pharma, Inc. (6.17%), Alpha Cognition Inc. (0.41%), Greenwich LifeSciences, Inc. (20.13%), Fate Therapeutics, Inc. (8.57%), Kalaris Therapeutics Inc. (10.01%), Molecular Partners AG Sponsored ADR (0.08%), Applied Therapeutics Inc. (6.34%), Nkarta, Inc. (12.14%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short Eagle Pharmaceuticals stock? Short selling EGRX is an investing strategy that aims to generate trading profit from Eagle Pharmaceuticals as its price is falling. EGRX shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eagle Pharmaceuticals? A short squeeze for Eagle Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EGRX, which in turn drives the price of the stock up even further. How often is Eagle Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EGRX, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies CTOR Short Squeeze IXHL Short Squeeze NVCT Short Squeeze ACOG Short Squeeze GLSI Short Squeeze FATE Short Squeeze KLRS Short Squeeze MOLN Short Squeeze APLT Short Squeeze NKTX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EGRX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
